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Background: Macrophage inhibitory cytokine 1 (MIC-1/GDF15) has been identified as a potential novel biomarker
for detection of pancreatic cancer (PCa). However, the diagnostic value of serum MIC-1 for pancreatic ductal
adenocarcinoma (PDAC), particularly for those at the early stage, and the value for treatment response monitoring
have not yet been investigated.
Methods: MIC-1 expression in tumor tissue was analyzed by RT-PCR from 64 patients with PDAC. Serum MIC-1
levels were detected by ELISA in 1472 participants including PDAC, benign pancreas tumor, chronic pancreatitis
and normal controls. The diagnostic performance of MIC-1 was assessed and compared with CA19.9, CEA and CA242,
and the value of it as a predictive indicator for therapeutic response and tumor recurrence was also evaluated.
Results: MIC-1 levels were significantly elevated in PDAC tissues as well as serum samples. The sensitivity of serum
MIC-1 for PDAC diagnosis was much higher than that of CA19.9 (65.8% vs. 53.3%) with similar specificities. Furthermore,
serum MIC-1 detected 238 out of 377 (63.1%) CA19.9-negative PDAC. Moreover, receiver operating characteristic (ROC)
curve analysis also showed that serum MIC-1 had a better performance compared with CA19.9 in distinguishing
early-stage PDAC from normal serum with a higher sensitivity (62.5% vs. 25.0% respectively). Notably, serum MIC-1 level
was significantly decreased in patients with PDAC after curative resection and returned to elevated levels when tumor
relapse occurred.
Conclusions: Serum MIC-1 is significantly elevated in most PDAC, including those with negative CA19.9 and early stage
disease, and thus may serve as a novel diagnostic marker in early diagnosis and postoperative monitoring of PDAC.Background
Pancreatic ductal adenocarcinoma (PDAC) accounts for
95% of pancreatic cancer (PCa) and has a dismal prog-
nosis, with only a 6% 5-year survival rate [1]. Owing to
diagnostic and therapeutic progress over the past de-
cades, the PDAC 5-year survival has been improved to
30-40% in about 15% patients who are eligible for poten-
tially curative therapies at the time of diagnosis [2,3].
Unfortunately, most of the patients with PDAC are diag-
nosed at an advanced stage due to the lack of obvious
symptoms, and their prognosis remains very dismal* Correspondence: zhangww1954@126.com
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unless otherwise stated.[4,5]. Thus, early detection and diagnosis of PDAC still
present the best chance for successful treatments and
improved outcomes.
CA19.9 has been widely used as a serologic diagnostic
tumor marker for PDAC, and its usefulness and clinical
significance have been reported in many studies [6,7].
However, serum CA19.9 is elevated in less than 50% of
early stage PDAC, and its efficacy for predicting progno-
sis and monitoring patients remains controversial. Many
alternative biomarkers, such as CEA and CA242, have
been investigated and used in clinical settings; but, their
diagnostic value for early PDAC has been limited
[6,8-10]. Therefore, it is necessary to identify new sero-
logic biomarkers with sufficient sensitivity to detect
PDAC at an early stage and with potential for predicting
prognosis and monitoring patients.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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25-kDa secreted growth factor of transforming growth
factor-β (TGF-β) super-family, was originally discovered
in macrophage cells [11,12]. MIC-1 is weakly and stably
expressed in most tissues under normal conditions, but
is substantially upregulated under pathological condi-
tions such as injury, inflammation and various cancers
[13-17]. Considerable evidence has indicated that MIC-1
plays a significant role in carcinogenesis related activ-
ities, such as proliferation, migration, apoptosis, and
angiogenesis, in many types of solid tumors including
PDAC [18-28]. A previous study identified MIC-1 as a
potential novel biomarker for detection of PCa [29-33].
However, the diagnostic value of serum MIC-1 for PDAC,
particularly for those at the early stage, and the value for
treatment response monitoring have not yet been investi-
gated comprehensively, which is the aim of this study.
Methods
Study population and sample preparation
We collected 64 paired PDAC tissue samples (cancer-
ous and matched adjacent normal tissues), which were
verified by post-surgical pathological examination (can-
cer institute and hospital, Chinese Academy of Medical
Sciences, Peking, China; CICAMS). Matched serum
samples were also obtained to investigate the relationship
between serum MIC-1 and tissue MIC-1 expression. All
the patients have undergone surgery at CICAMS from
2001 to 2008. The clinicopathologic characteristics of
these PDAC patients are summarized in Table 1. The cor-
responding normal tissues were obtained at least 2 cm
away from the primary tumor.Table 1 Characteristics of subjects with PDAC and controls
Tissue
samples
















Male 35 287 63 27 438
Female 29 213 52 23 369
Age (years)
≤45 23 102 26 17 111
46-55 25 153 34 14 215
56-65 14 121 29 12 272





IV 298For serum samples, we recruited 1472 subjects in the
discovery group and 100 subjects in the validation
group. The clinicopathologic characteristics of the par-
ticipants from above two groups are presented in Table 1.
The discovery group included 807 PDAC and 115 be-
nign pancreas tumors diagnosed between January 1,
2001 and December 31, 2010 (CICMAS, Peking, China),
50 chronic pancreatitis cases and 500 age- and gender-
matched healthy subjects (by physical examination). The
validation group included 50 stage I PDAC patients and
50 normal controls in the same hospital from December
2008 to November 2012. The samples from this inde-
pendent validation group were not included in the dis-
covery process and were evaluated in a blinded manner
(the statistician had no prior information related to the
samples) to avoid optimism in reporting performance.
We also recruited an additional 240 cases with colorec-
tal adenocarcinoma (n = 30), prostate adenocarcinoma
(n = 30), gastric adenocarcinoma (n = 30), ovarian car-
cinoma (n = 30), breast carcinoma (n = 30), thyroid car-
cinoma (n = 30), esophageal squamous cell carcinoma
(ESCC, n = 30) and non-small-cell lung carcinoma
(NSCLC, n = 30), as diagnosed by post-surgical patho-
logical examination (Table 2).
Additionally, serum samples at one month post-
surgery were collected from 102 of the 807 PDAC
patients undergoing curative resection without inflam-
matory complications in the discovery group. Of the
102 cases, 35 patients with relapsed disease were in-
cluded for monitoring the role of serum MIC-1 in re-
sponse to curative resection and early recurrence.





















57 17 19 28 31
45 14 16 22 19
30 4 8 15 16
38 4 13 12 14
23 9 8 12 13




Table 2 Characteristics of the subjects with eight types of
epithelial malignancies (n = 240) in addition to PDAC and
normal subjects
Pathological feature BC TC OC ESCC GA PA NSCLC CA
Cases (n) 30 30 30 30 30 30 30 30
Gender (n)
Male 0 14 0 17 16 30 15 18
Female 30 16 30 13 14 0 15 12
Age (years)
≤45 11 11 7 5 2 3 6 4
46-55 12 14 17 9 13 8 12 9
55-65 6 3 5 11 11 9 8 10
>65 1 2 1 5 4 10 4 7
Stage (n)
I 4 8 2 5 4 6 3 5
II 6 14 10 12 9 7 11 14
III 9 7 8 9 10 9 9 7
IV 11 1 10 4 7 8 7 4
BC: breast carcinoma; TC: thyroid carcinoma; OC: ovarian carcinoma; ESCC:
esophageal squamous cell carcinoma; GA: gastric adenocarcinoma; PA: prostate
adenocarcinoma; NSCLC: non-small-cell lung carcinoma; CA: colorectal
adenocarcinoma.
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curative resection.
None of the cases involved in our present study had
undergone chemotherapy or radiotherapy prior to sam-
pling, and subjects with inflammatory complications
were also excluded from this project. The pathological
evaluation was based on the criteria outlined by the
American Joint Committee on Cancer staging criteria.
This study has obtained human research ethics approval
from the Ethics Committee of CICAMS.Quantification of MIC-1 mRNA by real-time quantitative
RT-PCR
Total RNA of cancerous and matched normal tissues was
extracted using TRIzol (Invitrogen) and assessed by meas-
uring absorbance at 260 nm. Reverse transcription to
synthesize the first strand of cDNA was performed with
M-MLV reverse transcriptase (Promega). The resulting
cDNA was then subjected to real-time quantitative PCR
for the evaluation of the relative mRNA levels of MIC-1
and GAPDH (glyceraldehyde-3-phosphate dehydrogenase,
as an internal control) with the following primers:
MIC-1 forward: 5′-GGTGCTCATTC AAAAGACCGA-
3′ and reverse: 5′-CATTCCACAGGGCAGGACA-3′.G
APDH forward: 5′-CTCCTCCTGT TCGACAGTCA
GC-3′and reverse: 5′-CCCAATACGACCAAATCCGTT-3′.
Gene- specific amplification was performed using an
LightCycler 480 real-time PCR system (Life Technologies).The mix was preheated at 95°C (10 min), and amplified
at 95°C (30 sec) and 55°C (1 min) for 45 cycles. The
resolution curve was measured at 95°C for 15 sec, 55°C
for 15 sec and 95°C for 15 sec. The Ct (threshold cycle)
value of each sample was calculated from the threshold
cycles with the instrument’s software, and the relative
expression of MIC-1 mRNA was normalized to the
GAPDH value.Quantification of MIC-1 and other biomarkers by
immunoassay
Samples of venous blood were collected using the VACU-
ETTE blood collection system. Blood was centrifuged
for 10 minutes at 1700 × g. The serum was stored fro-
zen at −80°C until use. Samples were thawed once just
prior to analyses. We measured a panel of four markers,
namely CEA, CA19.9, CA242 and MIC-1. Serum levels of
MIC-1 were measured using a sensitive in house sandwich
ELISA produced by CICAMS, of which the detection limit
level was 20 pg/mL and the coefficient of variation
was <10% [34]. Briefly, 50 μl various concentrations of
standard recombinant MIC-1 and serum samples were
added to each well of a 96-well plate that has been coated
with 5 μg/ml of monoclonal anti-MIC-1 antibody (7C7,
one of self- developed anti-MIC-1 high-affinity anti-
bodies). Meanwhile, 50 μl 0.2 μg/ml of biotinylated rabbit
anti-MIC-1 polyclonal antibody was added and incubated
for 1 h at 37°C. After the plate was washed, streptavidin-
HRP conjugate was added and incubated for 0.5 h at 37°C.
Finally, the optical density of each well was determined
using a microplate reader set to 450 nm. All samples were
assayed in duplicate. Serum level of CEA and CA19.9
were detected by the related kit (Roche). Serum level of
CA242 was detected by CA242 assay kit (Abbott).Statistical analysis
The Kruskal–Wallis test and Mann–Whitney test were
used to compare the level of MIC-1 among all groups and
between unpaired groups, respectively. The Wilcoxon
test was used to compare MIC-1 level in paired serum
samples obtained before surgical tumor resection and
one month after surgical tumor resection as well as at
the time of recurrence. Spearman bivariate correlation
analysis was used to analyze the correlation. Receiver
operating characteristic (ROC) analysis was performed
to determine the diagnostic performance. Logistic re-
gression model was also fitted to combine diagnostic in-
formation of biomarkers. The level of MIC-1 mRNA in
tissues and protein in serum were described as mean ±
SEM and mean ± standard deviation, respectively. The
statistical analyses were performed with the statistical
package for the social sciences, version 13.0 (SPSS), and
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statistically significant.
Results
The overexpression of MIC-1 in PDAC tissues and the
correlation with serum MIC-1
First, we assessed the expression of MIC-1 in PDAC, and
found that MIC-1 was overexpressed in 81.0% (51/64) of
cancer tissues compared with their corresponding normal
tissues. Additionally, 75% of the 64 cases showed at least a
2-fold upregulation (Figure 1a). The results also showed
that increased expression of MIC-1 was not significantly
correlated with TNM classification (stage I: 0.063 ± 0.019,
stage II: 0.087 ± 0.018; P = 0.172), suggesting that the over-
expression of MIC-1 likely occurred in the early stages of
PDAC.
Based on our previous result that MIC-1 acts a
secretory protein, the correlation between MIC-1 pro-
tein expression levels in 64 paired PDAC tissues and
matched serum samples was also analyzed. We observed
a statistically significantly positive correlation between
MIC-1 expression in tumor tissues (0.077 ± 0.013) and
matched serum samples (2085.9 ± 1477.6 pg/mL) from
these patients (r = 0.569, P < 0.001; Figure 1b), and the
serum MIC-1 level in these patients with upregulated
expression of MIC-1 in tumor tissues (n = 51) was sig-
nificantly higher than that with down-regulated expres-
sion of MIC-1 (n = 13) (P =0.004; Figure 1c). Therefore,
we focused the rest of our study on serum MIC-1 for
further assessment of its efficacy as a diagnostic and
prognostic biomarker in patients with PDAC.
The elevated level of serum MIC-1 in PDAC and its
diagnostic potential
To evaluate the diagnostic potential of MIC-1, a total of
1472 serum samples, including those from patients with
PDAC (n = 807), benign pancreas tumor (n = 115), chronic
Pancreatitis (n = 50) and normal control subjects (n = 500)
were examined. In comparison with healthy control sub-
jects (416.8 ± 286.9 pg/mL), the levels of serum MIC-1
demonstrated a stepwise increase in patients with benign
pancreas tumor (808.4 ± 483.9 pg/mL; P < 0.001), chronic
Pancreatitis (1299.0 ± 709.6 pg/mL; P < 0.001) and PDAC
(1731.0 ± 1181.0 pg/mL; P < 0.001) (Figure 1d). The results
also showed that increased expression of MIC-1 was not
significantly correlated with TNM classification (P = 0.212,
Kruskal–Wallis test), which was consistent with the result
of MIC-1 expression in tissues, again suggesting that the
increased level of serum MIC-1 might occur in early stage
of PDAC.
To determine whether or not MIC-1 expression is
unique for PDAC, we also collected serum from 240 in-
dividuals prior to surgery. This included samples from
patients with eight different types of common epithelialmalignancies (Table 2). Quantitative ELISA revealed that
serum MIC-1 levels in PDAC were higher than in the
eight other cancers tested. We also found that, when
compared with normal controls (416.8 ± 286.9 pg/mL),
serum MIC-1 was elevated in non-small-cell lung
carcinoma (1258.0 ± 587.3 pg/mL; P < 0.001), gastric
adenocarcinoma (1154.0 ± 660.2 pg/mL; P < 0.001), ovarian
carcinoma (923.0 ± 442.7 pg/mL; P < 0.001), esophageal
squamous cell carcinoma (1018.0 ± 618.7 pg/mL; P < 0.001),
prostate adenocarcinoma (1167.0 ± 804.9 pg/mL; P < 0.001),
and colorectal adenocarcinoma (1371.0 ± 818.7 pg/mL;
P < 0.001); but there was no significant difference in
levels of MIC-1 in thyroid carcinoma (336.4 ± 172.2 pg/mL;
P = 0.132) and breast carcinoma (426.5 ± 264.0 pg/mL;
P = 0.856) (Figure 1e).
Better diagnostic performance of serum MIC-1 compared
with CA199, CEA and CA242 in PDAC
We next generated ROC curves to assess the potential
usefulness of serum MIC-1 as a noninvasive biomarker
for PDAC in the discovery group. Using the 500 normal
samples as negative controls, the area under the ROC
curve of MIC-1 for PDAC is higher than that of CA19.9,
CEA and CA242 (P < 0.001; Figure 2a). Using a cutoff
value of 1000 pg/ml, based on mean plus three standard
deviations of healthy subjects for the sake of usability in
clinical settings, the sensitivity, specificity, and positive
and negative predictive values of MIC-1 were 65.8%,
96.4%, 96.7%, and 63.6%, respectively, to identify a pa-
tient with PDAC. The sensitivity of MIC-1 for diagnosis
of PDAC was higher than that of CA19.9 (53.3%), CEA
(29.6%) and CA242 (48.9%) and demonstrated comparable
specificity. More importantly, the sensitivity of MIC-1 was
independent of serum CA19.9 levels (r = 0.066, P = 0.061).
Therefore, the diagnostic performance of serum MIC-1
was also carefully investigated in CA19.9-negative (<37
U/mL) PDAC. We noticed that serum MIC-1 had an
outstanding performance for distinguishing CA19.9-
negative pancreatic carcinomas from non–pancreatic
carcinoma controls including benign pancreas tumors
(AUROC, 0.886; 95% CI, 0.865–0.906; Figure 2b). These
results suggested that serum MIC-1 level is a much more
sensitive tumor marker compared to CA19.9 for the de-
tection of pancreatic carcinomas. MIC-1 demonstrated
superiority even in those PDAC with negative CA19.9
(<37 U/mL; n = 377), showing a median serum MIC-1 level
of 1253.3 pg/mL and a sensitivity of 63.1% (Figure 2c).
Moreover, multivariate logistic regression model indicated
that the combination of MIC-1 and CA19.9 could improve
the diagnostic performance significantly (AUROC, 0.957;
95% CI, 0.945 –0.967).
To explore the ability of MIC-1 as a single marker in
discriminating patients with PDAC from benign disease,
the control group involved subjects with chronic
Figure 1 The level of MIC-1 in PDAC tissue and serum samples. a. Upregulation of MIC-1 in tumor tissues and corresponding normal samples
in PDAC (y-axis: the MIC-1 mRNA expression level, described as 2-△Ct with log10 scale axis). b. Scatter plots showing the correlation between rela-
tive expression of MIC-1 levels in serum (y-axis: log10 scale) and matched tumor tissues (x-axis: log 10 scale) obtained from 64 patients. A positive
correlation was found by Spearman correlation (r = 0.569; P < 0.001). c. Relationship between serum MIC-1 and MIC-1 overexpression in 64 patients
with PDAC. d. Comparison of serum MIC-1 levels between the patients with PDAC and different controls. Serum MIC-1 levels of patients with PDAC
are significantly higher than that of different controls. e. Serum MIC-1 in other malignant neoplasms, including eight kinds of common tumors. In the
box plots, the lines denote 10th, 25th, median, 75th and 90th percentiles for each, using the Mann–Whitney U test.
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Our ROC analyses revealed that serum MIC-1 as a sin-
gle marker was insufficient to discriminate patients withPDAC from benign subjects, with an AUC value of
0.739, which was not found to be superior to serum
CA242 (0.739), CA19.9 (0.520) and CEA (0.619). At the
Figure 2 Comparison of the diagnostic performance of serum MIC-1, CA19.9, CEA and CA242 for PDAC. a. Sensitivities and specificities of
MIC-1 , CA19.9, CEA and CA242 for the diagnosis of PDAC was compared through the analyses of ROC curves in the discovery group (n = 1307).
AUROC curve of serum MIC-1 was much larger than that of CA19.9, CEA and CA242 (P < 0.001). b. The potential of serum MIC-1 for distinguishing
CA19.9-negative pancreatic carcinomas from non–pancreatic carcinoma controls including benign pancreas tumors. c. A similar positive rate
(present above the bar) of serum MIC-1 (using the cut off value 1000 pg/mL) was observed in patients with PDAC with different CA19.9 levels.
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tients with benign pancreas tumor exceeded the threshold;
in contrast, 8.7% (10 of 115), 15.7% (18 of 115) and 15.7%
(18 of 115), of these patients were above the cutoff value
of CA242, CA19.9 and CEA, respectively. Results also in-
dicated that MIC-1 (AUC, 0.592) is inferior to CA19.9
(0.684), CEA (0.620) and CA242 (0.739) in the distinction
of PDAC from chronic pancreatitis, which may be attrib-
uted to MIC-1’s association with inflammation.Performance of serum MIC-1 for the diagnosis of PDAC at
early stage and validation in another independent cohort
To evaluate the diagnostic performance of MIC-1 in
early detection and diagnosis of PDAC, we focused on a
subset of patients with early-stage PDAC (stage I and II;
n = 172). ROC curve analysis suggested that serum MIC-
1 had a better performance compared with CA19.9,
CA242 and CEA for distinguishing early-stage PDAC
from normal controls (Figure 3a). In detecting early-
Figure 3 The role of serum MIC-1 in the diagnosis of early stage PDAC. a. ROC curve analysis using serum MIC-1, CA199, CEA and CA242
levels for discriminating PDAC in discovery group. b. ROC curve analysis using serum MIC-1 levels for discriminating PDAC in validation group.
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ity of MIC-1 was much higher than that of CA19.9
(65.1% vs.43.0%); even in very early-stage pancreatic car-
cinomas (stage Ia; n = 16), MIC-1 showed an obviously
higher sensitivity of 62.5% compared to CA19.9’s sensi-
tivity of 25.0%. In addition, the combination of CA19.9
and MIC-1 further significantly improved the detection
rate of early PDAC (stage I and II) from 43.0% to 78.1%,
which was much higher than the simultaneous use of
CA19.9, CEA and CA242 (58.1%).
To further assess the robustness of the serum MIC-1
level as a novel early diagnostic marker in PDAC, we
blindly validated in another external, independent group
of 50 early-stage (stage I) PDAC and 50 healthy subjects
(the validation group; Figure 3b). The serum MIC-1 level
of PDAC (1357.0 ± 956.4 pg/mL; P < 0.001) was also sig-
nificantly increased compared with that of healthy popu-
lation (411.3 ± 190.5 pg/mL), which was quite similar to
that of the early-stage PDAC derived from the discovery
group.
The roles of serum MIC-1 levels in monitoring treatment
response of PDAC
We analyzed paired pre- and postoperative serum sam-
ples in a subset of 133 PDAC patients who underwent
surgical resection of their tumors. Among the 133 pa-
tients with PDAC, 102 underwent potentially curative
resection, whereas 31 underwent noncurative resection.
It was interesting to note that serum levels of MIC-1
(1728.0 ± 1218.0 pg/mL) were significantly reduced atone month after surgery (1280.0 ± 816.7 pg/mL; P < 0.001)
(Figure 4a). Furthermore, when data was analyzed based
on potentially curative vs noncurative surgeries, postoper-
ative reductions in serum MIC-1 levels occurred exclu-
sively among patients with potentially curative surgeries
(1650.0 ± 1124.0 vs 1092.0 ± 635.9 pg/mL; P < 0.001)
(Figure 4b). In contrast, no statistically significant dif-
ferences were observed in MIC-1 levels before (1984.0 ±
1479.0 pg/mL) or after surgery (1726.0 ± 907.5 pg/mL)
in patients with noncurative resections (P = 0.636)
(Figure 4c). Collectively, these data underscore the im-
portance of serum MIC-1 level as a potential bio-
marker for monitoring the treatment response of
PDAC.
At one month after potentially curative resection, serum
MIC-1 levels were significantly decreased from 1650.1 ±
1123.9 pg/mL to 1092.2 ± 635.9 pg/mL (P <0.001), a lower
level similar to that of benign pancreas tumor. Moreover,
in 35 cases with tumor relapse, the decreased serum
MIC-1 levels after operation (1110.0 ± 515.6 pg/mL)
were elevated again at the time of tumor recurrence
(1710.0 ± 946.5 pg/mL; P <0.001) (Figure 4d). A signifi-
cant correlation (r = 0.965; P < 0.001) was found be-
tween the baseline MIC-1 levels before the first
operation (1602.0 ± 998.4 pg/mL) and that at time of
tumor recurrence (1710.0 ± 946.5 pg/mL; P = 0.644)
(Figure 4e and f ). These data suggested that MIC-1
could be a sensitive tumor marker to monitor the treat-
ment response and post operation tumor recurrence in
patients with PDAC.
Figure 4 The role of MIC-1 in evaluating therapy response and surveillance of PDAC after curative resection. a. Comparison of serum
MIC-1 levels from all PDAC patients before surgery (Pre) and one month after postsurgical removal of primary tumors (Post). (n = 133). b. Comparison
of serum MIC-1 levels in 102 PDAC patients who underwent potentially curative surgeries. c. Comparison of serum MIC-1 levels in 31 PDAC patients
who underwent noncurative surgeries. d. In 35 patients with documented recurrence, the serum MIC-1 levels were increased again to the preoperative
levels. e. Comparison of serum MIC-1 levels between the baseline MIC-1 levels before the first operation and that at time of tumor recurrence
in 35 patients with recurrence. f. A significant correlation (r = 0.965; P < 0.001) was found between MIC-1 levels before the first operation and
after recurrence.
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Despite the variation of practice pattern worldwide, sur-
gical resection is the current therapeutic option with
curative intent for patients with PDAC [2,5]. The 5-year
survival rate after curative treatment for patients with
early stage PDAC is more than 30%, whereas the 5-year
survival rate for patients with advanced-stage disease re-
mains very dismal [1,3,4]. Therefore, early detection and
diagnosis of PDAC are extremely important in improv-
ing the survival of the patients. Currently, CA19.9 is still
the only widely used serologic tumor marker in screen-
ing and diagnosing PDAC; however, the sensitivity andspecificity is not satisfactory, especially for early stage
PDAC [6,7]. Although tremendous efforts have been ap-
plied to identify improved PDAC biomarkers such as
CA242, to date, it has not been shown to be superior to
CA19.9 in clinical performance [6,8-10,35]. Therefore,
an additional biomarker favoring early detection and
diagnosis of PDAC is still urgently needed. The present
study is the first large-scale investigation of the clinical
value of MIC-1 in PDAC. We analyzed the expression of
MIC-1 in PDAC tissues and sera, and found that the
serum levels of MIC-1 were elevated, which was consist-
ent with the results observed in the tissue samples.
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diagnostic indicator in early stage PDAC, and investi-
gated the potential of serum MIC-1 for predicting re-
sponse to therapies and tumor recurrence.
First, we found that the serum MIC-1 level of patients
with PDAC is significantly higher than that of healthy
controls, benign pancreas tumors and chronic pancrea-
titis populations, indicating that MIC-1 may serve as a
promising biomarker in diagnosis of PDAC. Further-
more, we have explored the serum levels of MIC-1 in
eight other common epithelial malignancies. The results
indicate that serum MIC-1 levels are higher in PDAC
patients than in patients with any of the other tumors
(p = 0.067 compared with colorectal adenocarcinoma,
each P < 0.05 compared with other seven tumor group),
which implies that high levels of MIC-1 may serve as a
promising biomarker in diagnosis of PDAC.
In our present study, we also compared the diagnostic
value for PDAC of MIC-1 with CA19.9, CEA and
CA242, which are often used as PDAC markers in clin-
ical settings, further demonstrating that the diagnostic
value of MIC-1 for PDAC was significantly better than
the other three markers. More importantly, the elevation
of serum MIC-1 was independent of CA19.9 level be-
cause a similar positive rate was observed when stratified
by different serum CA19.9 status and no correlation be-
tween these 2 markers was found. Even in those CA19.9-
negative PDAC, the serum MIC-1 level was also increased
dramatically and the diagnostic sensitivity was 63.1%,
which is much higher than that of the other reported bio-
marker such as serum CA242 and CEA in our study. The
combination of MIC-1 and CA19.9 could improve the
diagnostic performance significantly. These findings indi-
cate that MIC-1 may become a novel diagnostic tumor
marker to detect PDAC.
However, our ROC analyses revealed that serum MIC-
1 levels were insufficient to discriminate patients with
PDAC from benign pancreas tumors, with an AUC value
of 0.739, although this was found to be superior to serum
CA19.9 (0.520). At the cutoff value of 1000 pg/mL,
10.42% (12 of 115) of patients with benign pancreas tu-
mors exceeded the threshold; in contrast, 15.7% (18 of
115) of these patients were above the cutoff value of
CA19.9. These indicate that MIC-1 is a novel marker
with a comparative false-positive rate in diagnosing and
differentiating PDAC from benign pancreas tumors. In
addition, ROC curves showed a lower classification power
of MIC-1 with respect to CA19.9 among chronic pancrea-
titis and PDAC, which may be attributed to MIC-1’s asso-
ciation with inflammation.
Another interesting finding of our study is that MIC-1
showed a superior diagnostic performance compared to
CA19.9 in those PDAC with early stage disease (stage I
and II; sensitivity, 65.1% vs.43.0%). Even in those patientswith very early stage disease (stage Ia), MIC-1 showed a
much higher sensitivity of 62.5% compared to 25.0% in
CA19.9. In addition, the combination of CA19.9 and
MIC-1 further significantly improved the detection rate
of very early PDAC from 43.0% to 78.1%, which was
much higher than the simultaneous use of CA19.9, CEA
and CA242 (58.1%). Thus, the combination of MIC-1
and CA19.9 may be a promising strategy for early diag-
nosis of PDAC in the future. Additionally, we prelimin-
arily tested the serum MIC-1 in another independent
cohort of early stage PDAC and found it was signifi-
cantly elevated compared to the controls (P = 0.001). It
is undeniable that there are many differences in the pa-
tient populations studied for each marker and combin-
ation of markers. However, these results strongly indicate
that MIC-1 may serve as a more valuable tumor marker
than CA19.9 in early detection of PDAC.
Monitoring response to therapies and tumor recur-
rence is another important role of tumor markers. In
our present study, radical resection of PDAC resulted in
a significant reduction in serum MIC-1 to a lower level
that was similar to benign pancreas tumors, and the de-
creased serum MIC-1 was increased again at the time of
tumor recurrence. This led us to hypothesize that serum
MIC-1 may possibly play a role in the tumorigenesis and
progression of PDAC. Moreover, the results suggested
that monitoring of serum MIC-1 after surgery is useful
in evaluation of early recurrence. These findings need to
be explored further, as our sample size and the duration
of follow-up are limited for this analysis; however, these
findings do provide preliminary evidence of a relation-
ship between serum MIC-1 levels and MIC-1 recurrence
that warrants additional investigation. Moreover, most of
these PDAC were treated by non-curative surgery or
other curative therapies without detailed clinical data;
therefore, the association between MIC-1 level and sur-
vival was not analyzed in this study and will need to be
further investigated [36].
Although our current MIC-1 assay may become a
promising tool for PDAC, we acknowledge potential
limitation of using MIC-1 as a single biomarker for the
early detection of PDAC. Circulating serum MIC-1 has
been described in many solid cancers besides PDAC,
underscoring the need for being vigilant about organ
and disease specificity while investigating MIC-1 as soli-
tary biomarker for PDAC [33,37-40]. As a consequence,
it might be challenging to differentiate whether circu-
lating MIC-1 is specifically associated with PDAC itself
or if this is a common phenomenon that manifests dur-
ing progression of any cancer as a result of perturba-
tions in the host immune response [14,41]. Another
limitation, as indicated above, was the fact that MIC-1
alone may not be sufficient to distinguish PDAC from
chronic pancreatitis.
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In summary, our results provide compelling evidence for
the potential usefulness of serum MIC-1 as an additional
noninvasive diagnostic and therapeutic monitoring marker
in patients with PDAC, a concept that can be incorporated
into routine clinical practice in the not-so-distant future
pending validation in large-scale multicenter prospective
trials.
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